🚀 VC round data is live in beta, check it out!
Nuvectis Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nuvectis Pharma and similar public comparables like Fennec Pharmaceuticals, OmniAb, Camp4 Therapeutics, Saniona and more.
Nuvectis Pharma Overview
About Nuvectis Pharma
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Founded
2020
HQ
Employees
13
Website
Financials (LTM)
EV
$204M
Nuvectis Pharma Financials
Nuvectis Pharma reported last 12-month revenue of — and negative EBITDA of ($30M).
In the same LTM period, Nuvectis Pharma generated — in gross profit, ($30M) in EBITDA losses, and had net loss of ($30M).
Revenue (LTM)
Nuvectis Pharma P&L
In the most recent fiscal year, Nuvectis Pharma reported revenue of — and EBITDA of ($28M).
Nuvectis Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($30M) | XXX | ($28M) | XXX | XXX | XXX |
| Net Profit | ($30M) | XXX | ($26M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Nuvectis Pharma Stock Performance
Nuvectis Pharma has current market cap of $236M, and enterprise value of $204M.
Market Cap Evolution
Nuvectis Pharma's stock price is $8.90.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $204M | $236M | 0.0% | XXX | XXX | XXX | $-1.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNuvectis Pharma Valuation Multiples
Nuvectis Pharma trades at (6.8x) EV/EBITDA.
EV / Revenue (LTM)
Nuvectis Pharma Financial Valuation Multiples
As of April 20, 2026, Nuvectis Pharma has market cap of $236M and EV of $204M.
Equity research analysts estimate Nuvectis Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nuvectis Pharma has a P/E ratio of (7.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $236M | XXX | $236M | XXX | XXX | XXX |
| EV (current) | $204M | XXX | $204M | XXX | XXX | XXX |
| EV/EBITDA | (6.8x) | XXX | (7.4x) | XXX | XXX | XXX |
| EV/EBIT | (7.0x) | XXX | (7.4x) | XXX | XXX | XXX |
| P/E | (7.9x) | XXX | (8.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (12.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nuvectis Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Nuvectis Pharma Margins & Growth Rates
Nuvectis Pharma's revenue in the last fiscal year grew by —.
Nuvectis Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.1M for the same period.
Nuvectis Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 28% | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.1M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Nuvectis Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nuvectis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Fennec Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| OmniAb | XXX | XXX | XXX | XXX | XXX | XXX |
| Camp4 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Saniona | XXX | XXX | XXX | XXX | XXX | XXX |
| Sol-Gel Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nuvectis Pharma M&A Activity
Nuvectis Pharma acquired XXX companies to date.
Last acquisition by Nuvectis Pharma was on XXXXXXXX, XXXXX. Nuvectis Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Nuvectis Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNuvectis Pharma Investment Activity
Nuvectis Pharma invested in XXX companies to date.
Nuvectis Pharma made its latest investment on XXXXXXXX, XXXXX. Nuvectis Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Nuvectis Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nuvectis Pharma
| When was Nuvectis Pharma founded? | Nuvectis Pharma was founded in 2020. |
| Where is Nuvectis Pharma headquartered? | Nuvectis Pharma is headquartered in United States. |
| How many employees does Nuvectis Pharma have? | As of today, Nuvectis Pharma has over 13 employees. |
| Who is the CEO of Nuvectis Pharma? | Nuvectis Pharma's CEO is Ron Bentsur. |
| Is Nuvectis Pharma publicly listed? | Yes, Nuvectis Pharma is a public company listed on Nasdaq. |
| What is the stock symbol of Nuvectis Pharma? | Nuvectis Pharma trades under NVCT ticker. |
| When did Nuvectis Pharma go public? | Nuvectis Pharma went public in 2022. |
| Who are competitors of Nuvectis Pharma? | Nuvectis Pharma main competitors are Fennec Pharmaceuticals, OmniAb, Camp4 Therapeutics, Saniona. |
| What is the current market cap of Nuvectis Pharma? | Nuvectis Pharma's current market cap is $236M. |
| Is Nuvectis Pharma profitable? | No, Nuvectis Pharma is not profitable. |
| What is the current EBITDA of Nuvectis Pharma? | Nuvectis Pharma has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Nuvectis Pharma? | Current EBITDA multiple of Nuvectis Pharma is (6.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.